C12N 2760/12234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12234 (Use of virus or viral component as vaccine) appears on 25 US grants and 38 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 38
- Assignees
- 33
- Inventors
- 97
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 3 |
| 2014 | 1 | 3 |
| 2015 | 3 | 3 |
| 2016 | 3 | 5 |
| 2017 | 5 | 0 |
| 2018 | 2 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 6 |
| 2022 | 0 | 0 |
| 2023 | 4 | 3 |
| 2024 | 1 | 3 |
| 2025 | 3 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof24 Mar 2026US 12,584,116 B2Consejo Superior De Investigaciones Cientificas (Csic)
- Severe fever with thrombocytopenia syndrome virus9 Sep 2025US 12,409,216 B2I.D.Bio.
- Bunyavirales vaccine26 Aug 2025US 12,397,048 B2CureVac AG
- DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)13 May 2025US 12,296,001 B2The Wistar Institute of Anatomy and Biology
- Mammal-specific growth-defective arbovirus24 Sep 2024US 12,098,393 B2TenGen Biomedical Company
- Bunyavirales vaccine2 Apr 2026US 2026/0091101 A1CureVac AG
- Monoclonal Antibody A38 Against Rift Valley Fever Virus and Use11 Sep 2025US 2025/0282851 A1Academy of Military Medical Science, PLA
- Multivalent viral particles21 Nov 2024US 2024/0382580 A1Cornell University
- Bovine herpesvirus type 1 (bohv-1) quadruple gene deleted mutant14 Mar 2024US 2024/0084325 A1The Boards of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Novel vaccine adjuvant18 Jan 2024US 2024/0016925 A1Sl Vaxigen, Inc.
Most cited
By later US patents
- Virus-like particles, methods of preparation, and immunogenic compositions15US 9,045,727 B2Emory University · 2015
- Bunyavirales vaccine9US 11,602,557 B2Cure Vac SE · 2023
- Reverse genetic system for rift valley fever virus and uses thereof5US 8,084,248 B2Board of Regents, The University of Texas System · 2011
- Recombinant rift valley fever (RVF) viruses and methods of use4US 10,064,933 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2018
- Methods to produce bunyavirus replicon particles4US 9,109,199 B2Stichting Dienst Landbouwkundig Onderzoek · 2015